TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model

Autor: Moukengue, B. Brown, H.K. Charrier, C. Battaglia, S. Baud'huin, M. Quillard, T. Pham, T.M. Pateras, I.S. Gorgoulis, V.G. Helleday, T. Heymann, D. Berglund, U.W. Ory, B. Lamoureux, F.

Background: Osteosarcoma (OS) is the most common primary malignant bone tumour. Unfortunately, no new treatments are approved and over the last 30 years the survival rate remains only 30% at 5 years for poor responders justifying an urgent need of ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::a0a1eeced7c2a105a5144d049fca09c1
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077881

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma

Autor: Georges, S., Calleja, L. R., Jacques, C., Lavaud, M., Moukengue, B., Lecanda, F., Quillard, T., Gabriel, M. T., Cartron, P. -F, Baud Huin, M., Lamoureux, F., Dominique Heymann, Ory, B.

Publikováno v: Oncotarget
Oncotarget, Impact journals, 2018, 9 (87), pp.35726-35741. ⟨10.18632/oncotarget.26284⟩
Oncotarget, 2018, 9 (87), pp.35726-35741. ⟨10.18632/oncotarget.26284⟩
Oncotarget, 2018, 9, pp.35726-35741. ⟨10.18632/oncotarget.26284⟩
Scopus-Elsevier
Oncotarget, Impact journals, 2018, 9, pp.35726-35741. ⟨10.18632/oncotarget.26284⟩

International audience; The metastatic dissemination is a complex multistep process by which tumor cells from a primary site enter into the systemic circulation to finally spread at distant sites. Even if this mechanism is rare at the tumor level, it

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fae50b8733b2773c338344c4c4e60301
https://hal.archives-ouvertes.fr/hal-02103169

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.

Autor: Moukengue B; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France., Brown HK; Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; University of Sheffield, INSERM, European Associated Laboratory 'Sarcoma Research Unit', Medical School, S10 2RX, Sheffield, UK., Charrier C; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France., Battaglia S; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France., Baud'huin M; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France; CHU de Nantes, Nantes, France., Quillard T; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France., Pham TM; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden., Pateras IS; Department of Histology and Embryology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece., Gorgoulis VG; Department of Histology and Embryology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece; Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Faculty of Biology, Medicine and Health Manchester Cancer Research Centre, Manchester Academic Health Centre, The University of Manchester, Manchester, UK., Helleday T; Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden., Heymann D; Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; University of Sheffield, INSERM, European Associated Laboratory 'Sarcoma Research Unit', Medical School, S10 2RX, Sheffield, UK; INSERM, U1232, CRCINA, Institut de Cancérologie de l'Ouest, University of Nantes, Université d'Angers, Blvd Jacques Monod, 44805 Saint-Herblain, France., Berglund UW; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden., Ory B; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France., Lamoureux F; Université de Nantes, INSERM, U1238, Sarcomes osseux et remodelage des tissus calcifiés, Team 3, Epistress, Rue Gaston Veil, 44035 Nantes cedex, France. Electronic address: francois.lamoureux@univ-nantes.fr.

Publikováno v: EBioMedicine [EBioMedicine] 2020 Mar; Vol. 53, pp. 102704. Date of Electronic Publication: 2020 Mar 07.